Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.58 |
| ▸ | BRD4 | O60885 | 10/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PPIA | P62937 | 1/20 | 0.42 |
| ▸ | CTSV | O60911 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31190951 | 0.82 | MAOB (0.47) | CYP19A1BRD4MAOBMEN1KMT2A | |
| SCHEMBL26022683 | 0.82 | MAOB (0.47) | CYP19A1MAOBMEN1KMT2AMAPT | |
| SCHEMBL31190976 | 0.82 | MAOB (0.47) | CYP19A1MAOBMEN1KMT2AMAPT | |
| SCHEMBL26022674 | 0.82 | MAOB (0.47) | CYP19A1BRD4MAOBMEN1KMT2A | |
| SCHEMBL16875669 | 0.80 | MDM2 (0.42) | CYP19A1MEN1KMT2AMAPTCYP2C9 | |
| SCHEMBL5579678 | 0.77 | CYP19A1 (0.53) | CYP19A1BRD4MEN1KMT2AMAPT | |
| SCHEMBL31290998 | 0.76 | CRHBP (0.39) | CYP19A1BRD4MEN1KMT2AMAPT | |
| SCHEMBL31191034 | 0.76 | CRHBP (0.39) | CYP19A1BRD4MEN1KMT2AMAPT | |
| SCHEMBL18973787 | 0.75 | CYP19A1 (0.41) | CYP19A1BRD4MEN1KMT2AMAPT | |
| SCHEMBL10470640 | 0.75 | LTA4H (0.48) | CYP19A1MEN1KMT2AMAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122029177-A | Oligonucleotides containing multiple ligands and/or lipids | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20250161459-A1 | TRKB LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2025-05-22 | — | — | US | disclosed |
| WO-2025038963-A1 | OLIGONUCLEOTIDES CONTAINING MULTIPLE LIGANDS AND/OR LIPIDS | ADARX PHARMACEUTICALS, INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| EP-4475837-A2 | TRKB LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | Adarx Pharmaceuticals, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| CN-118973616-A | Trkb ligand conjugated compounds and uses thereof | 阿达尔克斯制药有限公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2024220930-A2 | MAPT-MODULATING COMPOSITIONS AND METHODS OF USE THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| WO-2023154896-A2 | TRKB LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161459-A1 | TRKB LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | NTRK2, NTRK1, BDNF | CYP19A1 2464/4885BRD4 1678/4885MAOB 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.